Zoetis Appoints Iris Knobloch to Board of Directors, Bringing Global Media, Consumer Strategy and Digital Expertise

Zoetis Inc., the global animal-health company listed on the New York Stock Exchange under the ticker ZTS, has appointed Ms. Iris Knobloch to its Board of Directors, effective 1st of December 2026. The appointment, announced on 13 October, will expand the board from 12 to 13 members and adds senior leadership experience spanning international media, consumer businesses, digital transformation and corporate governance.

The appointment is notable for an animal-health business whose growth increasingly depends not only on medicines and vaccines, but also on understanding pet owners, strengthening brands, using digital tools and serving customers across diverse international markets.

Who is Iris Knobloch?

Knobloch is an international business leader with experience across media, entertainment, finance, hospitality and consumer-facing businesses. Her career includes senior executive roles at WarnerMedia and its predecessor companies, as well as leadership and board positions at several major organisations.

• President, Festival de Cannes: She has held the position since July 2022 and became the first woman to lead the film festival.

• Chair, Deezer S.A.: She became chair of the music-streaming company’s board in January 2023.

• Director, Lazard Inc.: She has served on the financial-services company’s board since April 2018.

• Director, Vail Resorts Inc.: She joined its board in February 2024.

• Former Chair and CEO, I2PO S.A.: She led the investment company from 2021 until July 2022, before its business combination with Deezer.

Her earlier experience also includes international relations and European strategic policy at Time Warner, and legal practice at O’Melveny & Myers and Noerr, Stiefenhofer & Lutz. She holds a doctorate in law from Ludwig Maximilian University of Munich and a Master of Laws from New York University.

Why the appointment matters for Zoetis

Zoetis develops medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for veterinarians, livestock producers and pet owners in more than 100 countries. The company’s announcement highlights Knobloch’s experience in consumer strategy, digital transformation, international leadership and global board governance.

Her appointment brings experience from industries in which customer relationships, brand positioning, technology adoption and international market execution are central to business strategy. That experience could be relevant to several areas of Zoetis’ business:

3. Global strategy and brand stewardship

Her international leadership and experience across regulated markets could be relevant as Zoetis manages its global portfolio, commercial priorities and customer relationships. These are potential areas of contribution, not announced changes to company strategy.

These implications are an industry analysis of the experience she brings; Zoetis has not announced specific business decisions arising from her appointment.

Board governance and appointment timeline

Source: Zoetis announcement and reporting on the appointment.

Zoetis Chief Executive Officer Kristin Peck welcomed Knobloch’s consumer-strategy, technology and global brand experience. Board Chair Michael McCallister also highlighted her international leadership and understanding of consumer behaviour as relevant to the company’s long-term strategy. Knobloch said she looked forward to supporting Zoetis in finding innovative ways to create value for customers and the animals in their care.

Industry perspective: broader experience at board level

The appointment reflects the breadth of expertise that a large, global animal-health company can draw on at board level. Alongside scientific research, regulatory compliance, manufacturing and veterinary expertise, animal-health businesses operate in markets shaped by consumer expectations, digital delivery, brand trust and international commercial execution.

Knobloch’s background is primarily in international business leadership and governance rather than animal-health research or veterinary medicine. Her contribution will therefore be most directly associated with the broader strategic and commercial perspective she brings to the board. The announcement does not indicate that she will take on an operational management role.

For the wider animal-health industry, the development is worth tracking as companies continue to combine established pharmaceutical and vaccine portfolios with diagnostics, digital services and customer-facing solutions. Whether this appointment leads to specific strategic changes will become clearer through future company disclosures.

What to watch next

• 1 December 2026: Knobloch’s appointment becomes effective.

• Board and committee disclosures: Monitor Zoetis’ governance filings for details of her board responsibilities.

• Future strategy updates: Watch for company announcements on digital solutions, customer engagement and international growth.

• Investor disclosures: Subsequent filings may provide further detail on director compensation and governance arrangements.

The appointment announcement establishes the effective date and the expansion of the board. It does not, by itself, establish any expected financial impact or a change in Zoetis’ business outlook.